Lucia Milla, MD
Rheumatology · Kingston, NYNPI 1184186587
Payments from drug & device makers
Across 126 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$615
- AbbVie$431
- Amgen$260
- Novartis$188
- GSK$162
- AstraZeneca$158
- plus $746 from 20 others
What the payments were for
- Food & beverage$2,48097%
- Education$803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 18 | $615 |
| AbbVie | 28 | $431 |
| Amgen | 13 | $260 |
| Novartis | 13 | $188 |
| GSK | 8 | $162 |
| AstraZeneca | 11 | $158 |
| UCB, Inc. | 4 | $106 |
| Viiv Healthcare Company | 4 | $96 |
| Pfizer | 3 | $82 |
| Merck | 4 | $68 |
| Bayer | 4 | $65 |
| Radius Health, Inc. | 2 | $47 |
| Sanofi | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Organon | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$126
How this compares
$2,560 in reported general payments places this provider in the 50th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 17 | $121,131 |
| Enbrel SureclickEtanercept | 15 | $100,349 |
| Xeljanz XrTofacitinib Citrate | 16 | $93,018 |
| Hydroxychloroquine Sulfate | 26 | $1,331 |
| MethotrexateMethotrexate Sodium | 47 | $988 |
| Prednisone | 25 | $177 |
| Alendronate Sodium | 14 | $137 |
| Allopurinol | 11 | $104 |
| Folic Acid | 14 | $57 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Kingston
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- David GoddardBrooklyn$3.9M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.